The stock market has attracted very many investors. With the right strategy and information, individuals are making huge profits from their stock investments. Sahm Adrangi is one of the leading stock market experts with a vast experience in the sector. For a long time, he has been helping entrepreneurs with tips on the right companies to invest in or avoid in the stock market. His experience has grown over the years, and his determination has made him a successful stock market expert. He attended Yale University where he earned a degree in economics. On top of that, Adrangi has worked at Longacre Fund Management, Deutsche Bank and Chanin Capital Partners.
Currently, he is the chief investment officer at Kerrisdale Capital Management which he founded in 2009. The firm specializes in special event-driven situations and long-term value investments. It has become the number one investment manager due to Sahm’s expertise and experience. Sahm researches and gives reports on various investment opportunities in the stock market. His primary aim is helping investors and businessmen avoid companies whose share value are high and will collapse soon due to various factors. His company stands to benefit when the shares value of the target companies drops.
Sahm Adrangi has researched East Kodak Company whose shares are high at the moment. This company has developed KodakOne and KodakCoin which seems not to benefit their shareholders. Sahm Adrangi is certain that the shares value of the company will go down as the company is working with companies with dubious backgrounds. Also, the company is experiencing revenue decline which Sahm believes will not be saved by recently announced partnerships.
When it comes to biopharmaceutical companies, Sahm Adrangi has researched on many companies including Proteostasis Therapeutics, Inc. According to his research, PTI-428 is not effective. This drug was released by Proteostasis Therapeutics, and after the release, the company’s shares value went up. Sahm Adrangi is sure that the shares value will go down soon, as his report indicated that the drug is ineffective in treating cystic fibrosis.